203 related articles for article (PubMed ID: 29624723)
1. Randomized, clinical trial of RT001: Early signals of efficacy in Friedreich's ataxia.
Zesiewicz T; Heerinckx F; De Jager R; Omidvar O; Kilpatrick M; Shaw J; Shchepinov MS
Mov Disord; 2018 Jul; 33(6):1000-1005. PubMed ID: 29624723
[TBL] [Abstract][Full Text] [Related]
2. Double blind trial of a deuterated form of linoleic acid (RT001) in Friedreich ataxia.
Lynch DR; Mathews KD; Perlman S; Zesiewicz T; Subramony S; Omidvar O; Vogel AP; Krtolica A; Litterman N; van der Ploeg L; Heerinckx F; Milner P; Midei M
J Neurol; 2023 Mar; 270(3):1615-1623. PubMed ID: 36462055
[TBL] [Abstract][Full Text] [Related]
3. A randomized, double-blind, placebo-controlled phase 2 study to assess safety, tolerability, and efficacy of RT001 in patients with amyotrophic lateral sclerosis.
Weemering DN; Midei M; Milner P; Gopalakrishnan V; Kumar A; Dannenberg AJ; Bunte TM; Foucher J; Ingre C; Ķēniņa V; Rallmann K; van den Berg LH; van Eijk RPA
Eur J Neurol; 2023 Dec; 30(12):3722-3731. PubMed ID: 37550954
[TBL] [Abstract][Full Text] [Related]
4. Double-blind, randomized and controlled trial of EPI-743 in Friedreich's ataxia.
Zesiewicz T; Salemi JL; Perlman S; Sullivan KL; Shaw JD; Huang Y; Isaacs C; Gooch C; Lynch DR; Klein MB
Neurodegener Dis Manag; 2018 Aug; 8(4):233-242. PubMed ID: 30051753
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich's ataxia: an exploratory, open-label, dose-escalation study.
Libri V; Yandim C; Athanasopoulos S; Loyse N; Natisvili T; Law PP; Chan PK; Mohammad T; Mauri M; Tam KT; Leiper J; Piper S; Ramesh A; Parkinson MH; Huson L; Giunti P; Festenstein R
Lancet; 2014 Aug; 384(9942):504-13. PubMed ID: 24794816
[TBL] [Abstract][Full Text] [Related]
6. Safety and tolerability of carbamylated erythropoietin in Friedreich's ataxia.
Boesch S; Nachbauer W; Mariotti C; Sacca F; Filla A; Klockgether T; Klopstock T; Schöls L; Jacobi H; Büchner B; vom Hagen JM; Nanetti L; Manicom K
Mov Disord; 2014 Jun; 29(7):935-9. PubMed ID: 24515352
[TBL] [Abstract][Full Text] [Related]
7. Oral lecithin and linoleic acid in Friedreich's ataxia: I. Design of the study, material and methods.
Melancon SB; Dallaire L; Potier M; Vanasse M; Marois P; Geoffroy G; Barbeau A
Can J Neurol Sci; 1982 May; 9(2):151-4. PubMed ID: 7049340
[TBL] [Abstract][Full Text] [Related]
8. Plasma and Red Blood Cell Membrane Accretion and Pharmacokinetics of RT001 (bis-Allylic 11,11-D2-Linoleic Acid Ethyl Ester) during Long Term Dosing in Patients.
Brenna JT; James G; Midei M; Heerinckx F; Atwal P; Milner P; Schmidt K; van der Ploeg L; Fielding R; Shchepinov MS
J Pharm Sci; 2020 Nov; 109(11):3496-3503. PubMed ID: 32871154
[TBL] [Abstract][Full Text] [Related]
9. Oral lecithin and linoleic acid in Friedreich's ataxia: III. Biochemical results.
Melancon SB; Dallaire L; Potier M; Cousineau J; Vanasse M; Geoffroy G; Fontaine G; Grignon B
Can J Neurol Sci; 1982 May; 9(2):165-9. PubMed ID: 6896672
[TBL] [Abstract][Full Text] [Related]
10. Deferiprone in Friedreich ataxia: a 6-month randomized controlled trial.
Pandolfo M; Arpa J; Delatycki MB; Le Quan Sang KH; Mariotti C; Munnich A; Sanz-Gallego I; Tai G; Tarnopolsky MA; Taroni F; Spino M; Tricta F
Ann Neurol; 2014 Oct; 76(4):509-21. PubMed ID: 25112865
[TBL] [Abstract][Full Text] [Related]
11. GIFT-1, a phase IIa clinical trial to test the safety and efficacy of IFNγ administration in FRDA patients.
Marcotulli C; Fortuni S; Arcuri G; Tomassini B; Leonardi L; Pierelli F; Testi R; Casali C
Neurol Sci; 2016 Mar; 37(3):361-4. PubMed ID: 26621361
[TBL] [Abstract][Full Text] [Related]
12. Oral lecithin and linoleic acid in Friedreich's ataxia: II. Clinical results.
Melancon SB; Vanasse M; Geoffroy G; Barabe L; Proulx A; Fontaine G; Dallaire L; Potier M
Can J Neurol Sci; 1982 May; 9(2):155-64. PubMed ID: 7049341
[TBL] [Abstract][Full Text] [Related]
13. Strong correlations among four measures of disease progression in Friedreich's ataxia.
Saal HJ; Heerinckx F; Zawadzki R; Omidvar O; Kilpatrick M; Zesiewicz T
Mov Disord; 2018 Jul; 33(6):1021-1022. PubMed ID: 29624733
[No Abstract] [Full Text] [Related]
14. Safety and efficacy of (+)-epicatechin in subjects with Friedreich's ataxia: A phase II, open-label, prospective study.
Qureshi MY; Patterson MC; Clark V; Johnson JN; Moutvic MA; Driscoll SW; Kemppainen JL; Huston J; Anderson JR; Badley AD; Tebben PJ; Wackel P; Oglesbee D; Glockner J; Schreiner G; Dugar S; Touchette JC; Gavrilova RH
J Inherit Metab Dis; 2021 Mar; 44(2):502-514. PubMed ID: 32677106
[TBL] [Abstract][Full Text] [Related]
15. Idebenone in Friedreich's ataxia.
Tonon C; Lodi R
Expert Opin Pharmacother; 2008 Sep; 9(13):2327-37. PubMed ID: 18710357
[TBL] [Abstract][Full Text] [Related]
16. Biological and clinical characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS) cohort: a cross-sectional analysis of baseline data.
Reetz K; Dogan I; Costa AS; Dafotakis M; Fedosov K; Giunti P; Parkinson MH; Sweeney MG; Mariotti C; Panzeri M; Nanetti L; Arpa J; Sanz-Gallego I; Durr A; Charles P; Boesch S; Nachbauer W; Klopstock T; Karin I; Depondt C; vom Hagen JM; Schöls L; Giordano IA; Klockgether T; Bürk K; Pandolfo M; Schulz JB
Lancet Neurol; 2015 Feb; 14(2):174-82. PubMed ID: 25566998
[TBL] [Abstract][Full Text] [Related]
17. Can rehabilitation improve the health and well-being in Friedreich's ataxia: a randomized controlled trial?
Milne SC; Corben LA; Roberts M; Murphy A; Tai G; Georgiou-Karistianis N; Yiu EM; Delatycki MB
Clin Rehabil; 2018 May; 32(5):630-643. PubMed ID: 29072092
[TBL] [Abstract][Full Text] [Related]
18. Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial.
Di Prospero NA; Baker A; Jeffries N; Fischbeck KH
Lancet Neurol; 2007 Oct; 6(10):878-86. PubMed ID: 17826341
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Omaveloxolone in Friedreich's Ataxia: Delayed-Start Analysis of the MOXIe Extension.
Lynch DR; Chin MP; Boesch S; Delatycki MB; Giunti P; Goldsberry A; Hoyle JC; Mariotti C; Mathews KD; Nachbauer W; O'Grady M; Perlman S; Subramony SH; Wilmot G; Zesiewicz T; Meyer CJ
Mov Disord; 2023 Feb; 38(2):313-320. PubMed ID: 36444905
[TBL] [Abstract][Full Text] [Related]
20. Effect of lecithin on disability and plasma free-choline levels in Friedreich's ataxia.
Chamberlain S; Robinson N; Walker J; Smith C; Benton S; Kennard C; Swash M; Kilkenny B; Bradbury S
J Neurol Neurosurg Psychiatry; 1980 Sep; 43(9):843-5. PubMed ID: 7420107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
